WHO ICTRP trial
Phase I study of SH003
KCT0007878 · Clinical Research Information Service (CRIS) · Not Recruiting
Key facts
| Trial ID | KCT0007878 |
|---|---|
| Public title | Phase I study of SH003 |
| Scientific title | A Phase I study of SH003 for Evaluate Safe Dose Range in Patients with Solid Cancer |
| Primary sponsor | Kyung Hee University |
| Registry | Clinical Research Information Service (CRIS) |
| Recruitment status | Not Recruiting |
| Study type | Interventional Study |
| Phase | Phase1 |
| Countries | Korea, Republic of |
| Conditions | Neoplasms |
| Interventions | Drug : Oral administration of SH003 for 3 weeks 1st dose group: 3 times a day, 4 tablets at a time (SH003 400mg per tablet) 2nd dose group: 3 times a day, 6 tablets at a time (SH003 400mg per tablet) 3rd dose group: 3 times a day, 8 tablets… |
| Registration date | Nov 3, 2022 |
| Target size | 18 |
| Registry page | cris.nih.go.kr |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: